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Introduction
A primary role for adipocytes is energy storage. Adipocytes can synthesize energy rich triacylglycerol from glucose or simply store fats transported by very low-density lipoproteins. The compact, anhydrous fat droplets holding triacylglycerol within adipocytes can conveniently sustain energy requirements over periods of starvation that likely affected our hunter-gatherer ancestors. However, the discovery of leptin in 1994 1 has shifted our vision of adipose tissue toward that of an active endocrine tissue. 2 To date, many more adipocyte-secreted molecules have been identified. Collectively termed adipokines, these molecules regulate whole body homeostasis through endocrine 3 and autocrine/ paracrine activities. 4 It is now also clear that the maladaptation of adipocytes to over-nutrition in obesity is causative to metabolic dysfunction. Dietary overload and an inactive lifestyle are modern phenomena leading to excess accumulation of body fat responsible for a chronic inflammatory disease that is tightly connected to insulin resistance, thereby linking obesity with its metabolic complications. 5 This inflammation does not rely on the classic instigators of immune responses, e.g., infection or tissue injury, which initiate the recruitment of leukocytes toward affected tissues. Rather, it is an immunological response to adipose tissue malfunction. This type of inflammation is referred to as parainflammation 6 and is dependent on white adipose tissue (WAT) infiltration by macrophages. [7] [8] [9] Mechanisms involved in the selfmaintenance of this inflammatory state in response to chronic caloric overload are currently being investigated. Evidence suggests that adipocytes and adipose tissue resident macrophages (ATMs) secrete bioactive molecules including inflammatory and anti-inflammatory cytokines that could be related to the development of low-grade systemic inflammation and insulin resistance. [10] [11] [12] [13] [14] Studies have shown that nuclear receptors are intracellular points of convergence for metabolism and inflammation. In the past decade, several nuclear receptors have been identified as sensors for dietary lipids that regulate transcriptional programs of key metabolic pathways. Recent findings further highlighted a role for nuclear receptors in the pathophysiology of the metabolic syndrome through the control of adipocyte function and ATM activation. This review will discuss the mechanisms by which nuclear receptors modulate WAT signaling and how the activities of nuclear receptors in WAT relate to the metabolic complications of obesity. A report of the link between chronic inflammation, ATMs and metabolic diseases will be presented, followed by discussion of the involvement of nuclear receptors in maintaining homeostasis within WAT. We will also review recent evidence for nuclear receptors in ATM function, focusing on the paracrine interaction between adipocytes and ATMs.
Adipose Tissue: An Important Source of Metabolic Inflammation
An increase in fat mass as a result of sustained positive energy balance correlates with changes in endocrine and metabolic functions. Notably, WAT from obese individuals show increases in inflammatory mediators, such as tumor necrosis factor-a (TNF-a), 10 interleukin 6 (IL-6), 15 inducible nitric oxide synthase (iNOS), 16 tumor growth factor β1 (TGF-β1), 17 and monocyte chemotactic protein-1 (MCP-1). 11 In addition to adipocytes, the stromal-vascular fraction of WAT contains a heterogenic cellular population, including endothelial cells, pre-adipocytes/fibroblasts, macrophages and other immune cells (e.g., T cells and eosinophils). In 2003, two reports provided the first evidence that obesity is associated with increased presence of macrophages in WAT in mouse models of obesity. These studies identified gene transcripts encoding proteins distinctive of macrophages in perigonadal fat tissues. 8, 9 Gene expression in macrophage and non-macrophage cells from WAT also showed that ATMs are the main source of TNF-a and other pro-inflammatory molecules in adipose tissue. 8, 9 Based on the results in mice, histological studies in human showed that the quantity of macrophage in WAT correlated positively with body mass index and adipocyte size. 8 Follow-up studies demonstrated that human visceral WAT, the accumulation of which is associated with alteration in lipid profile and insulin sensitivity, [18] [19] [20] [21] [22] [23] also contains macrophages in greater number in obesity. 12 In paired biopsies obtained from obese adults during bariatric surgery, there were twice as many macrophages in visceral as in subcutaneous WAT. 24 Similar to the results derived from mouse models, studies of human WAT showed that non-adipocyte cells were the main sources of inflammatory cytokines. 7, 12 Analysis of adipose tissue in obesity shows the convergence of macrophages on adipocytes of necrotic appearance, described as "crown-like structures." 25 Collectively, these findings suggest that WAT in the obese state is associated with sustained inflammation, characterized by excessive macrophage infiltration.
The M1/M2 Dichotomy of Adipose Tissue Macrophages
Identification of different subsets of macrophages in WAT represents a second significant finding in understanding the pathogenesis of metabolic diseases. Macrophages are heterogeneous, with phenotypic differences associated with differential expression patterns of cytokines, surface markers and metabolic enzymes. Two separate states are commonly used to define macrophage activation, although they likely represent extremes of a continuum. Pro-inflammatory mediators and microbial triggers, such as the bacterial lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria, induce M1 or "classically activated" macrophages. M1 macrophages produce pro-inflammatory cytokines (e.g., TNF-a, IL-6 and IL-1β) and reactive oxygen species such as nitric oxide via activation of iNOS. Whereas the M1 macrophages are essential for removal of pathogens, long-lasting activation of this phenotype is considered to be deleterious to body homeostasis. In contrast, the M2 or "alternatively activated" macrophage produces IL-10 to suppress inflammation (for reviews see refs. 26 and 27) . Following the reports that obesity increases macrophage infiltration in WAT, it was shown that diet-induced obesity is also associated with a change in the polarization of ATMs from the M2 state in lean mice to a predominantly M1 proinflammatory state. 13 Therefore, the balance between M1 and M2 macrophages controls the progression of immune responses in WAT, which is thought to have a key role in the development of metabolic diseases (Fig. 1) .
Links Between Inflammation and Insulin Resistance
Evidence supporting pro-inflammatory signaling-dependent induction of metabolic dysfunction preceded our understanding of adipocyte/macrophage interactions. Data exists showing a positive correlation between macrophage infiltration of visceral fat and the severity of hepatic damage in obese patients. 24 Specific knockout experiments in the myeloid lineage provide insights into the involvement of macrophages in the anomalies of the metabolic syndrome. However, these studies did not specify ATM contributions.
Suppression of inflammation in obesity improves insulin resistance. Hotamisligil et al. first observed that WAT and circulating TNF-a protein levels were elevated in obese rodents, as compared with lean controls. Neutralization of TNF-a action with a recombinant soluble TNF-a receptor in obese fa/fa rats caused an increase in peripheral glucose uptake in response to insulin. 10 The definitive proof that inflammation and increased cytokine levels in obesity are responsible for insulin resistance was obtained four years later using genetic models of mice lacking TNF-a or TNF-a receptors. Absence of TNFa signaling resulted in improved insulin sensitivity in both diet-induced obese mice and the ob/ob model of obesity.
14 Inflammatory signaling pathways, including that of TNFa, are mediated by several protein kinases, such as IkB kinase (IKKs) and c-Jun N-terminal kinases (JNKs). Mice lacking Ikk-β, a regulator of inflammatory responses through activation of NFkB (nuclear factor kappa B), in myeloid cells are protected from insulin resistance. 28 Studies on JNK1 action during development of insulin resistance support a common mechanism through which JNK1 activation in insulin target cells directly interferes with insulin signaling.
29 Jnk1
mice exhibit a lean phenotype, are protected from diet-induced obesity and have reduced expression of pro-inflammatory mediators such as IL-6, TNFa, IL-1β, migration inhibitor factor and MCP-1, compared with wild-type mice. Subsequent work demonstrated that removal of Jnk1 in the non-hematopoietic tissues protects mice from insulin resistance caused by high fat diet, partly through decreased adiposity. Jnk1 deletion from hematopoietic cells has no effect on adiposity but confers protection against high fat diet-induced inflammation and insulin resistance. 30 However, this latter result was not reproducible in a separate study. 31 Lastly, MCP-1, a chemokine that recruits macrophages, and its receptor CCR2, have been shown to promote insulin resistance. 11, 32 Interestingly, addition of MCP-1 to mature adipocytes in vitro decreased insulin-stimulated glucose uptake and the expression of several adipogenic genes, suggesting that chemokines may have a direct impact on metabolic homeostasis, in addition to their role in mediating immune cell infiltration.
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Loss of alternatively activated macrophages facilitates insulin resistance. Using mouse models in which macrophage alternative activation (M2) was genetically impaired, susceptibility to dietinduced obesity, hepatic steatosis, insulin resistance and glucose intolerance all increased. 33, 34 We will discuss these studies in greater details below.
Macrophage insulin signaling in inflammation and metabolic diseases. Insulin signaling is thought to affect macrophage function. However, mechanistic insights in this area are lacking. Studies have shown that deletion of the gene Sorb1 encoding Cbl-associated protein (Cap), a molecule implicated in insulinstimulated glucose uptake, protects against high fat diet-induced insulin resistance and reduces inflammation. The insulin sensitivity phenotype could be transferred to wild-type mice on high fat diet by transplantation of Sorb1 2/2 bone marrow, 35 supporting a role for macrophage insulin signaling in modulation of systemic insulin sensitivity. Studies in atherosclerosis with insulin receptor knock out macrophages show conflicting results. In the background of LDL receptor knockout mice, these macrophages show an impaired ability to handle ER stress-induced apoptosis leading to worsening of atherosclerotic plaques. 36 In contrast, insulin receptor and apoE double knockout macrophages were associated with less inflammation and smaller atherosclerotic lesions. 37 
The Origin of Metabolic Inflammation in Obesity
The mechanism underlying metabolic dysfunction/obesity induced chronic inflammation is still unclear. The so-called "portal hypothesis" proposes that increased lipolysis in the visceral fat of obese individuals exposes the liver to high concentrations of free fatty acids (FFA), eventually contributing to liver insulin resistance. 38 Similar effects from FFA are seen in other tissues, such as muscle and pancreas (a process termed lipotoxicity, for a review see ref. 39) . FFA have been shown to directly activate the macrophage M1 response in vitro (Fig. 2) . For example, toll-like receptor 4 (TLR4), the receptor for LPS, was shown to mediate the effects of FFA on inflammation. The capacity of FFA to induce inflammatory signaling and cytokine expression in adipocytes and macrophages is decreased in the absence of TLR4. Furthermore, Tlr4 2/2 mice are protected from diet-induced insulin resistance. 40 While it is known that visceral WAT has higher levels of lipolysis and contains more ATMs than abdominal subcutaneous WAT, [41] [42] [43] recent studies have characterized the effects of weight loss and fasting on ATMs in mice and identified a role for lipolysis in macrophage recruitment. 44 First, increases in ATM number correlate with plasma concentrations of FFA and adipose tissue lipolysis. Second, dietary and genetic modifications aimed at reducing lipolysis or weight gain decreased ATM accumulation. Finally, macrophage/adipocyte co-cultures suggested that local lipid fluxes are important regulators of ATM activation. Taken together, these studies are consistent with the possibility that within WAT, pro-inflammatory adipokines and FFA play a major role in the initiation of chronic inflammation and metabolic dysregulation that are observed in obesity (Fig. 2) .
Lipid Sensing Nuclear Receptors in Adipose Tissue Homeostasis
Although the findings discussed above strongly suggest a link between increased adiposity, systemic inflammation and insulin Figure 1 . White adipose tissue and the metabolic complications of obesity. In addition to its function in energy storage, adipose tissue is now considered an endocrine organ, producing circulating molecules, including adipokines (e.g., leptin and adiponectin), inflammatory mediators (e.g., TNF-a, IL-6, IL-1b and MCP-1) and bioactive lipids (e.g., FFA) that have important impacts on metabolic homeostasis. The maladaptation of adipocytes in response to chronic positive energy balance leads to increased production of pro-inflammatory chemokines/cytokines and release of non-esterified FFA, resulting in the infiltration of pro-inflammatory macrophages (M1) and a shift in the balance between pro-and anti-inflammatory (M2) macrophage populations within white adipose tissues. This so called "para-inflammation" or metabolic inflammation is associated with obesity-related metabolic syndrome.
resistance through the activation of ATMs, a critical unanswered question is whether ATM activation can be modulated pharmacologically. Since certain nuclear receptors act as sensors for dietary fats and are also involved in the regulation of inflammation, they represent attractive druggable targets to control metabolic inflammation and associated diseases. We will focus on members of the fatty acid sensing peroxisome proliferatoractivated receptor (PPAR) family, as they are known to regulate adipocyte function and macrophage immune response and as such, play an important role in WAT homeostasis.
The Transcriptional Action of Nuclear Receptors
Nuclear receptors are ligand-activated transcription factors responsible for the control of diverse biological processes. 45 The biochemical studies that first described the action of steroid hormones provided a general mode of action for a large family of nuclear receptors responsive to a variety of lipophilic signaling molecules, including steroids, retinoids, dietary lipids and xenobiotics. 46 Most of the receptors contain a conserved structure with a heterogeneous N-terminal domain, a central DNA binding domain and a C-terminal ligand-binding domain, responsible for ligand binding, receptor dimerization and ligand-dependent activation of transcription. 46 Several members in this superfamily, such as PPARs, liver X receptors (LXRs), farnesoid X receptor (FXR) and the retinoid-related orphan receptors (RORs), are thought to be metabolic sensors, as their ligands include fatty acids and cholesterol derivatives. Activation of these receptors, notably PPARs and LXRs, using synthetic ligands improves metabolic homeostasis. 47 Nuclear receptors modulate gene expression through recruitment of large protein complexes, which modify the structure of chromatin through histone modification (Fig. 3) . Unliganded receptors interact with co-repressors, most notably silencing mediator of retinoic and thyroid hormone receptors (SMRT) and nuclear receptor co-repressor (NCoR), which recruit histone deacetylases (HDACs), particularly HDAC3, to deacetylate histones leading to a tighter chromatin structure and less accessible promoters. 48, 49 Co-activators such as PPARc coactivator-1a (PGC-1a) and steroid receptor coactivators (SRC1/2/3) and histone acetylases (p300/CBP) are recruited to ligand-bound nuclear receptors to upregulate gene expression. [50] [51] [52] Ligand-dependent repression of inflammatory gene expression by nuclear receptors is less understood and is mediated by several unconventional mechanisms (described below).
Nuclear Receptors and Adipocyte Function
The PPARs (PPARa, β/d and c) are activated by dietary fatty acids and have been shown to modulate various cellular functions, mostly related to fat transport, storage and oxidation. PPARc in particular has been well studied in its regulation of adipose tissue. The mammalian PPARc was cloned by analysis of the adiposespecific enhancer from the adipocyte protein 2 (ap2) gene, an adipocyte-specific fatty-acid binding protein. 53 It later became clear that PPARc is needed for adipocyte differentiation and maintenance in vivo [54] [55] [56] [57] [58] and that anti-diabetic drugs, thiazolidinediones (TZDs), were synthetic ligands for PPARc. 59, 60 It is thought that TZDs improve insulin sensitivity partly through promoting fatty acid storage as triglycerides in adipocytes, thereby reducing lipotoxicity. PPARd, on the other hand, is a regulator of fat burning. 61 In genetically predisposed mouse models of obesity (db/db), overexpression of constitutively active PPARd in adipocytes induces expression of genes involved in fatty acid oxidation and energy dissipation, which leads to reduced adiposity and improved lipid profiles. 62 Treatment of db/db mice with a PPARd agonist improves insulin sensitivity, while PPARddeficient mice show reduced energy expenditure. 63 PPARd is also involved in brown adipose tissue (BAT) metabolism. Unlike WAT that stores excess energy in the form of triacylglycerol, BAT dissipates energy as heat. In BAT, PPARd regulates mitochondrial oxidative metabolism and thermogenesis through PGC-1a. 64 PGC-1a is a cold-inducible, master regulator of mitochondrial biogenesis. 65, 66 The SRC co-activators also play a role in adipocyte differentiation and BAT thermogenesis. 65, [67] [68] [69] The role of co-repressors in PPAR-mediated lipid metabolism is more complex. Disruption of SMRT-PPARc interaction leads to spontaneous differentiation of pre-adipocytes to adipocytes. 70 Increased SMRT-PPAR interaction in vivo causes obesity, premature aging and related metabolic diseases due to suppressed fatty acid oxidation and mitochondrial oxidative metabolism. 71, 72 Finally, recent work has identified NCoR as a negative regulator of adipogenesis both in vivo 73 and in vitro.
74 Figure 2 . Adipose tissue macrophages and the origin of metabolic inflammation. In obesity, adipose tissue resident macrophages exhibit an M1/pro-inflammatory phenotype. They are activated either by systemic chronic inflammation before entering adipose tissues or by locally produced inflammatory mediators. Histologically, they are seen to be concentrated around dying fat cells (insert, top panel). These M1 macrophages produce pro-inflammatory cytokines (e.g., TNF-a and IL-1b) known to induce metabolic dysfunction and insulin resistance in neighboring adipocytes through inflammatory signaling kinases (e.g., JNK and IKKs), creating an unresolvable inflammatory response.
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Nuclear Receptors and Macrophage Activation
The notion that PPARc is critical for adipocyte differentiation prompted investigation of similar functions in other cell types. Early studies showed that PPARc was involved in a signaling pathway controlling differentiation in monocytic cells, 75, 76 although later work using genetic models of PPARc 2/2 mice showed that macrophage differentiation was not critically dependent on PPARc. 77, 78 These studies initiated a new field of research examining the regulatory effects of nuclear receptors on inflammation. We now know that in addition to the well characterized immuno-suppressive activity of glucocorticoid receptor, activation of several nuclear receptors, particularly PPARs and LXRs, are able to modulate macrophage activation through several anti-inflammatory mechanisms or by Th2 polarization.
Anti-inflammatory mechanisms. Previous work examining anti-inflammatory effects of PPARs was conducted mainly in the macrophage in the context of vascular inflammation and atherosclerosis. However, PPARs are expressed in several cell types in the vasculature (e.g., immune cells, endothelial cells and smooth muscle cells) and have been shown to inhibit the production of several inflammatory mediators and cytokines in these cells. For example, treatment with PPARa agonist fenofibrate in patients with hyperlipidemia and atherosclerosis decreases circulating levels of fibrinogen, IL-6, CRP, IFN-c and TNF-a. 79, 80 In aortic smooth muscle cells, PPARa inhibits the expression of classical mediators of inflammation such as IL-6 and cyclooxygenase-2 via repression of NFkB signaling. 79 PPARc activation inhibits the expression of iNOS, gelatinase B and scavenger receptor A in response to the prostaglandin D2 metabolite, 15-deoxy-prostaglandin J2 (15dPGJ2), and synthetic PPARc ligands. 81 PPARc expression was shown to be induced by IL-4 in macrophages 82 and was later demonstrated to have a crucial role in macrophage M2 polarization (discussed below). It was proposed that PPARc inhibited inflammation by antagonist actions on the activities of inflammatory transcription factors, including activator protein 1 (AP-1), NFkB and signal transducer and activator of transcription 1 (STAT1). However, several synthetic and natural PPARc agonists at higher concentrations produce anti-inflammatory responses through PPARc-independent mechanisms, such as the direct inhibition and modification of IKK-β. 83 The Glass laboratory identified a transrepression Figure 3 . Mechanisms of nuclear receptor action in the macrophage. Nuclear receptors, in the form of homo-or heterodimers, regulate transcription through differential recruitment of co-repressors (e.g., SMRT and NCoR) and co-activators (e.g., SRCs and PGC-1s). In the absence of ligand, nuclear receptors recruit co-repressor complexes to actively repress transcription. Upon ligand binding, the conformation of the receptor changes, releasing the co-repressor complex and recruiting co-activator complexes to activate transcription of target genes. There are at least three different mechanisms by which nuclear receptors regulate target gene expression. The ligand-dependent inhibition of inflammatory gene expression involves unconventional mechanisms (right). In the transrepression model, the liganded nuclear receptor is SUMOylated by SUMO ligase Pias1, which is then recruited to promoters of NFkB target genes to block degradation of co-repressor complexes. In the repressor sequestration model, unliganded-PPARd/SMRT sequesters the repressor BCL-6 by direct interaction. Upon ligand binding, BCL-6/SMRT dissociates from PPARd to repress pro-inflammatory target genes. Liganded PPARd also controls the expression of M2 genes, thereby promoting macrophage alternative activation.
mechanism whereby liganded nuclear receptors actually repress transcription of inflammatory genes through post-translational modifications and protein-protein interactions. 84 In this model, ligand-bound PPARc is SUMOylated, which in turn recruits NCoR co-repressor complexes to directly repress NFkB target genes (Fig. 3) . 85 Similar mechanisms were subsequently identified for glucocorticoid receptor 86 and LXR. 87, 88 Compared with the other PPARs, less is known about the roles of PPARd in inflammation. PPARd agonists also inhibit LPS-inducible genes. 89 Lee et al. proposed a unique transcriptional pathway through which PPARd exerts its anti-inflammatory effects by sequestering the transcriptional repressor BCL-6 away from the promoters of inflammatory genes, such as MCP-1, IL-1β and MMP-9.
90 BCL-6 is released from ligand-activated PPARd and becomes available to inhibit inflammatory gene expression (Fig. 3) .
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Th2 polarization. Th2 cytokines, particularly IL-4 and IL-13, mediate M2 activation. 26 The observation that both PPARc and PPARd levels in macrophages are increased by IL-4/IL-13 initiated closer examination of the role of macrophage PPARs in mouse models of diet-induced obesity. 33, 34, [92] [93] [94] [95] In the macrophage, IL-4/IL-13-induced alternative activation is associated with increased fatty acid β-oxidation and oxidative metabolism, programs that are transcriptionally controlled by PPARc and PPARd. 33, 34, 94, 96, 97 Accordingly, PPARd and PPARc were shown to regulate the expression of certain M2 genes and control alternative activation in the macrophage. 33, 34, 93 Mice with myeloid specific deletion of PPARd or PPARc show increased M1 and decreased M2 markers in WAT and liver. 33, 34, 92, 93, 98 Of note, in a separate study, mice lacking PPARc or PPARd in hematopoietic cells did not show expected metabolic phenotypes. 99 Interestingly, STAT6, a Th2 transcription factor, was shown to facilitate the PPARc response to IL-4 at the transcriptional level in macrophages, with the net effect being an increase in the number of regulated genes and in the magnitude of responses. 100 
Nuclear Receptors in Paracrine Interaction of Adipose Tissue Resident Macrophages with Adipocytes
Given their important functions in adipocytes and macrophages, activation of PPARs is expected to improve WAT homeostasis and reduce metabolic inflammation. In adipocytes, PPARc and PPARd reduce fatty acid efflux by promoting fat storage or burning, respectively (Fig. 4) . In macrophages, PPARs can suppress inflammatory responses by anti-inflammatory mechanisms or by Th2 polarization. In fact, myeloid-specific PPAR deletion experiments described above are consistent with the notion that the beneficial activities of PPARs may rely in part on their anti-inflammatory properties. PPARc deletion in macrophages is associated with impaired glucose tolerance and insulin resistance in response to a high fat diet. 33 Additionally, it has been demonstrated that the insulin sensitizing effect of rosiglitazone was decreased when PPARc was inactivated in macrophages. 92 Kang et al. proposed a paracrine pathway in which adipose tissuederived IL-13 activates macrophage PPARd to modulate M2 activation (Fig. 4) . 34 Disruption of this pathway by myeloidspecific PPARd gene deletion leads to WAT inflammation, hepatosteatosis and systemic insulin resistance. Collectively, these studies support the notion that the dynamics between adipocytes and ATMs play a key role in the initiation of chronic inflammation and demonstrate that the PPAR signaling pathway serves as an important regulatory node in the control of lipid-induced metabolic stress and "para-inflammation." Figure 4 . Role of PPARs in the paracrine interaction between adipocytes and adipose tissue macrophages. As sensors of dietary fatty acids, PPARs play an important role in maintenance of white adipose tissue homeostasis. In adipocytes, PPARc activation reduces fatty acid efflux by promoting fat storage and increasing adiponectin production, which improves systemic lipid and glucose metabolism. In the macrophage, PPARs can suppress inflammatory responses by anti-inflammatory mechanisms or by Th2 polarization, which increases the production of an anti-inflammatory cytokine, IL-10. Th2 cytokines are produced locally by many cell types (eosinophils, T lymphocytes, mast cells and adipocytes) to activate downstream transcription factors in the macrophage, including STAT6 and PPARd/PPARc. Studies have demonstrated that disruption of the IL-13-PPARd paracrine pathway leads to white adipose tissue inflammation and insulin resistance, highlighting the importance of PPAR signaling in controlling the initiation of metabolic inflammation.
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Conclusion
At the signaling level, inflammatory and metabolic processes are integral and linked to components of metabolic diseases. Modulation of the activities of nuclear receptors is a potential therapeutic strategy to restore the imbalance of pro-inflammatory and anti-inflammatory signaling for preventing and/or treating obesity-related metabolic and cardiovascular diseases that are thought to be triggered by unresolved, chronic inflammation. In fact, PPAR agonists are currently used to treat type 2 diabetes and dyslipidemia. However, the side effects of PPARc ligands in cardiovascular complications have limited their use. Future studies aiming to isolate localized effects of PPARs within the WAT microenvironment, either through targeting tissue-specific coactivators/co-repressors or identifying selective synthetic modulators, will provide new therapeutic opportunities. New mechanistic insights derived from these studies will also help define relative contributions from PPAR signaling in adipocytes or immune cells in the control of metabolic inflammation and associated diseases.
